Mesirow Financial Investment Management Inc. Sells 30,105 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Mesirow Financial Investment Management Inc. cut its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 49.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,447 shares of the biotechnology company's stock after selling 30,105 shares during the quarter. Mesirow Financial Investment Management Inc.'s holdings in ADMA Biologics were worth $609,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new stake in ADMA Biologics in the 2nd quarter valued at approximately $17,886,000. D. E. Shaw & Co. Inc. grew its position in ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock worth $76,298,000 after purchasing an additional 1,442,799 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock valued at $23,872,000 after purchasing an additional 1,059,394 shares during the last quarter. Castleark Management LLC acquired a new stake in ADMA Biologics in the first quarter valued at about $5,400,000. Finally, Hillsdale Investment Management Inc. increased its holdings in shares of ADMA Biologics by 41,893.3% in the 1st quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company's stock valued at $4,157,000 after purchasing an additional 628,400 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Trading Down 3.1 %

NASDAQ ADMA traded down $0.70 during trading on Tuesday, reaching $21.78. 4,184,408 shares of the stock traded hands, compared to its average volume of 3,669,687. The firm has a market cap of $5.08 billion, a price-to-earnings ratio of 78.75 and a beta of 0.64. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The stock's 50-day moving average price is $18.22 and its 200 day moving average price is $14.06.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 59.29%. During the same period in the prior year, the company posted $0.01 earnings per share. Analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

Wall Street Analyst Weigh In

ADMA has been the subject of several recent research reports. Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright upped their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday. Finally, Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the company's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the firm's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares of the company's stock, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the firm's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the sale, the chief operating officer now directly owns 449,088 shares of the company's stock, valued at approximately $7,589,587.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 466,900 shares of company stock valued at $8,224,121 over the last three months. 3.70% of the stock is currently owned by insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.